ITM is a privately owned biotechnology and radiopharmaceutical group of companies dedicated to the development, production and global supply of targeted diagnostic and therapeutic radiopharmaceuticals and radioisotopes for use in cancer treatment. We are developing a proprietary portfolio and growing pipeline of targeted treatments in various stages of clinical development addressing cancers such as neuroendocrine cancers or bone metastases. Our main objectives are to significantly improve treatment outcomes and quality of life for cancer patients through a new generation of Targeted Radionuclide Therapies in Precision Oncology. The headquarters are located in the heart of the research center of the Technical University of Munich (TUM).
In the United States, ITM is expanding to support our growing portfolio and pipeline. We are building a high-performing commercial team to bring innovative radiopharmaceutical therapies to patients and strengthen our presence in oncology.
We are seeking a highly experienced Director / Head of Pharmacovigilance (US) to establish and lead our US PV presence within a globally integrated, EU‑headquartered pharmacovigilance organization.
This role is critical in ensuring that US regulatory requirements are effectively implemented within a globally led PV system, without creating a standalone or siloed US function. The successful candidate will act as a key bridge between the US and EU headquarters, ensuring alignment, consistency, and compliance across regions.
During the initial 12–24 months, this role requires a hands-on leader who can both build the function and contribute operationally, in close collaboration with the Global PV/QPPV Office.
We would like to fill the following permanent vacancy in a hybrid working model in Princeton as soon as possible
